Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Nvidia is under pressure as traders debate the boards investigation into CEO Jensen Huang following reports of an affair with a woman suspected of ties to China, with some fearing national-security scrutiny or Huangs departure while others see the controversy as overblown. The community is split between continued selling and buying the dip ahead of earnings, with some also pointing to broader tech weakness.

Hims & Hers is under pressure after its quarterly report showed an unexpected loss, margin compression and a reduced profit outlook, despite strong revenue growth; traders also point to a sequential subscriber decline. Some investors see the planned Peptides+ launch and Andrew Hubermans board role as potential growth drivers, while skeptics question whether those initiatives can offset profitability and execution concerns.

Digital Turbines quarterly results triggered a sharp selloff despite revenue growth and a higher sales outlook, as gross-margin compression and unchanged profit guidance raised concerns about whether growth is translating into earnings. Traders are divided between viewing the drop as an overreaction and worrying that margin pressure and debt could weigh on the turnaround.

MARAs quarterly report has focused attention on its AI/HPC pivot: traders welcomed debt reduction, a share-repurchase authorization and an initial GPU-services contract, while noting that larger AI tenant leases remain unannounced. Reactions are split over whether the pivot can diversify the business, with skeptics emphasizing the revenue miss, Bitcoin-price exposure and execution risks.

A third-quarter earnings beat, stronger-than-expected Q4 guidance, and an expanded buyback authorization sparked a sharp rally that quickly faded as traders weighed managements cautious tone and slowing underlying growth. Bulls see progress toward a turnaround, while skeptics point to declining year-over-year revenue, temporary revenue tailwinds, and doubts about management; the result has been intense debate over whether the report signals recovery or a sell-the-news move.

PEPEs volatile rebounds and repeated tests of a key round-number resistance are drawing attention, with traders often pointing to relative strength when the broader crypto market weakens. Bulls see the bounces as signs of accumulation or a renewed meme-coin run, while skeptics warn the rallies may fade and emphasize the sharp pullbacks.

TTWO is drawing attention ahead of Grand Theft Auto VIs release, with traders focused on managements report of preorder demand far above expectations and the stocks rebound despite weaker recurring spending and an unchanged bookings outlook. Bulls see the blockbuster as a growth catalyst, while skeptics argue expectations may already be priced in and question whether sales will translate into sustained cash flow.

Candels latest SITC immune-response and viral-shedding data for aglatimagene are drawing attention as the company prepares a planned FDA application for its prostate-cancer treatment, following positive Phase 3 results. Bulls see the data as strengthening the filing package, while skeptics focus on submission timing, manufacturing and management transparency; recent share weakness is also attributed by some traders to broader biotech-market pressure.

Attention centers on the FDAs Nov. 22 decision on Capricors Deramiocel, with the current application emphasizing upper-limb function in Duchenne muscular dystrophy. The HOPE-3 cardiac datas American Heart Association award and physician support have bolstered bullish sentiment, while concerns about FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication keep approval uncertain.

Senseonics Q3 results, marked by sharply higher revenue and raised full-year guidance, are driving attention and a sharp rally. Many traders welcome the commercial progress, while others question whether it can offset ongoing losses and cash needs, and warn that gains may not hold.